VBL Therapeutics VB-201 drug reduces IBD severity
VBL Therapeutics, a clinical stage biotechnology company, has announced that its drug candidate, VB-201, was found effective in attenuating inflammatory bowel disease (IBD) in preclinical models.

Alvine ALV003 drug meets primary endpoint in Phase 2a study
Alvine Pharmaceuticals' drug compound, ALV003, has met the primary endpoint in diminishing gluten-induced intestinal mucosal injury in well-controlled celiac disease patients, in a Phase 2a trial.

Peregrine reports top-line data from bavituximab study
Peregrine Pharmaceuticals has announced positive results from its randomised, double-blind, placebo-controlled Phase 2b trial investigating two dose levels of bavituximab plus docetaxel versus docetaxel plus placebo in patients with second-line, non-small cell lung cancer (NSCLC).

Ipsen, Active Biotech conclude half of planned recruitment in tasquinimod study
Active Biotech and Ipsen have announced that 600 patients have been recruited in the global, pivotal, randomised, double-blind, placebo-controlled Phase 3 study of tasquinimod, used to treat patients with metastatic castrate-resistant prostate cancer (CRPC).

Meet Biovian at the Biotech Outsourcing Strategies Conference
Meet Biovian at the Biotech Outsourcing Strategies cmc2012 (BOS cmc) on 14 June 2012 at the Sohuset Conference Center, Denmark. Biovian's director of business development and projects, Dr Knut Ringbom, will be available for in-depth discussions with delegates at the conference.

Meet Biovian at Lyckad Läkemedelsutveckling in Stockholm
Meet Biovian at 'Lyckad Läkemedelsutveckling' seminar on 31 May 2012 at Hotel Grand, Stockholm, Sweden. Biovian's Director of Business Development and Projects, Dr Knut Ringbom will be available for in-depth discussions with delegates at Biovian's stand.

Fujifilm Diosynth Biotechnologies Invests in New Equipment and Labs at UK Facility
Fujifilm Diosynth Biotechnologies has completed the first phase of a £3m ($4.5m) investment in new equipment and laboratories at its Billingham, UK site.

Tissue Solutions Achieves Certification to ISO 9001
Tissue Solutions is pleased to announce that it has been awarded ISO 9001:2008 BSI accreditation.